FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902172360> ?p ?o ?g. }

• W2902172360 endingPage "2396" @default.
• W2902172360 startingPage "2385" @default.
• W2902172360 abstract "Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy Paola Faverio,1,2 Giulia Bonaiti,1,2 Francesco Bini,3 Adriano Vaghi,3 Alberto Pesci1,2 1School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; 2Respiratory Unit, San Gerardo Hospital, ASST di Monza, Monza, Italy; 3ASST-Rhodense, UOC Pneumologia, Garbagnate Milanese, Milan, Italy Abstract: Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that binds to free IL-5. It induces bone marrow eosinophil maturation arrest and decreases eosinophil progenitors and subsequent maturation in the blood and bronchial mucosa. Its use has been extensively studied in severe eosinophilic asthma at a dose of 100 mg subcutaneously (SC) every 4 weeks and, more recently, in other hypereosinophilic syndromes. Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic vasculitis that may involve multiple organs. Characteristic clinical manifestations are asthma, sinusitis, transient pulmonary infiltrates and neuropathy. Among the numerous pathways involved in the pathogenesis of EGPA, the Th-2 phenotype has a main role, as suggested by the prominence of the asthmatic component, in triggering the release of key cytokines for the activation, maturation and survival of eosinophils. In particular, IL-5 is highly increased in active EGPA and its inhibition can represent a potential therapeutic target. In this scenario, mepolizumab may play a therapeutic role. After some positive preliminary observations on the use of mepolizumab in small case series of EGPA patients with refractory or relapsing disease despite standard of care treatment, a randomized controlled trial was published in 2017. Mepolizumab at a dose of 300 mg administered by SC injection every 4 weeks proved effective in prolonging the period of remission of the disease, allowing for reduced steroid use. The positive results of this study, which met both of the primary endpoints, led to the approval in the USA of mepolizumab in adult patients with EGPA by the Food and Drug Administration in 2017. Therefore, mepolizumab can be officially considered as an add-on therapy with steroid-sparing effect in cases of relapsing or refractory EGPA. However, the most appropriate dose and duration of therapy still need to be determined. Future studies on larger multinational populations with prolonged follow-up are warranted. Keywords: mepolizumab, eosinophilic granulomatosis with polyangiitis, Churg–Strauss syndrome" @default.
• W2902172360 created "2018-12-11" @default.
• W2902172360 creator A5004445358 @default.
• W2902172360 creator A5038572083 @default.
• W2902172360 creator A5039286904 @default.
• W2902172360 creator A5065246682 @default.
• W2902172360 creator A5081483998 @default.
• W2902172360 date "2018-12-01" @default.
• W2902172360 modified "2023-10-05" @default.
• W2902172360 title "Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy" @default.
• W2902172360 cites W1517672737 @default.
• W2902172360 cites W1555620450 @default.
• W2902172360 cites W1574141134 @default.
• W2902172360 cites W1691880693 @default.
• W2902172360 cites W174387549 @default.
• W2902172360 cites W1965304178 @default.
• W2902172360 cites W1972474621 @default.
• W2902172360 cites W1974262000 @default.
• W2902172360 cites W1977238362 @default.
• W2902172360 cites W1979554068 @default.
• W2902172360 cites W1980010384 @default.
• W2902172360 cites W1983812092 @default.
• W2902172360 cites W1988294817 @default.
• W2902172360 cites W1988708695 @default.
• W2902172360 cites W1988758075 @default.
• W2902172360 cites W1989396329 @default.
• W2902172360 cites W1991436369 @default.
• W2902172360 cites W1992648705 @default.
• W2902172360 cites W1994585625 @default.
• W2902172360 cites W1995577762 @default.
• W2902172360 cites W1995682991 @default.
• W2902172360 cites W2000650705 @default.
• W2902172360 cites W2001028378 @default.
• W2902172360 cites W2005186531 @default.
• W2902172360 cites W2005694123 @default.
• W2902172360 cites W2007357409 @default.
• W2902172360 cites W2008930833 @default.
• W2902172360 cites W2017813372 @default.
• W2902172360 cites W2020673179 @default.
• W2902172360 cites W2029899280 @default.
• W2902172360 cites W2031517139 @default.
• W2902172360 cites W2031558950 @default.
• W2902172360 cites W2033559734 @default.
• W2902172360 cites W2038284056 @default.
• W2902172360 cites W2040613743 @default.
• W2902172360 cites W2045329903 @default.
• W2902172360 cites W2045581365 @default.
• W2902172360 cites W2050068982 @default.
• W2902172360 cites W2050962284 @default.
• W2902172360 cites W2053597373 @default.
• W2902172360 cites W2055192969 @default.
• W2902172360 cites W2060277916 @default.
• W2902172360 cites W2060688537 @default.
• W2902172360 cites W2061276567 @default.
• W2902172360 cites W2062118334 @default.
• W2902172360 cites W2062918919 @default.
• W2902172360 cites W2066755714 @default.
• W2902172360 cites W2072998173 @default.
• W2902172360 cites W2075699130 @default.
• W2902172360 cites W2082911490 @default.
• W2902172360 cites W2095754126 @default.
• W2902172360 cites W2097446240 @default.
• W2902172360 cites W2106779701 @default.
• W2902172360 cites W2107254198 @default.
• W2902172360 cites W2108438457 @default.
• W2902172360 cites W2108789073 @default.
• W2902172360 cites W2113969469 @default.
• W2902172360 cites W2124223181 @default.
• W2902172360 cites W2128411850 @default.
• W2902172360 cites W2128427657 @default.
• W2902172360 cites W2130911389 @default.
• W2902172360 cites W2133417821 @default.
• W2902172360 cites W2138355864 @default.
• W2902172360 cites W2141225393 @default.
• W2902172360 cites W2142587628 @default.
• W2902172360 cites W2144276864 @default.
• W2902172360 cites W2150534327 @default.
• W2902172360 cites W2155730304 @default.
• W2902172360 cites W2156123924 @default.
• W2902172360 cites W2160891054 @default.
• W2902172360 cites W2162759126 @default.
• W2902172360 cites W2264075806 @default.
• W2902172360 cites W2288102166 @default.
• W2902172360 cites W2332327479 @default.
• W2902172360 cites W2417394351 @default.
• W2902172360 cites W2552116544 @default.
• W2902172360 cites W2604291894 @default.
• W2902172360 cites W2604703565 @default.
• W2902172360 cites W2615817830 @default.
• W2902172360 cites W2741652982 @default.
• W2902172360 cites W2756335179 @default.
• W2902172360 cites W2757963532 @default.
• W2902172360 cites W2769957315 @default.
• W2902172360 cites W2795629650 @default.
• W2902172360 cites W2802833453 @default.
• W2902172360 cites W4205457468 @default.
• W2902172360 doi "https://doi.org/10.2147/tcrm.s159949" @default.
• W2902172360 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6292233" @default.

• next